Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-Dose Nivolumab Combined With Chemotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: JOAO A SOLER, MD
- Phone Number: +55 17 981350180
- Email: joao.soler@hbonco.org.br
Study Contact Backup
- Name: ALINE FARES, MD
- Email: aline.fares@edu.famerp.br
Study Locations
-
-
SAO Paulo
-
Sao Jose Do Rio Preto, SAO Paulo, Brazil, 15090000
- Recruiting
- Fundação Faculdade Regional de Medicina de São José do Rio Preto
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to provide a signed Informed Consent Form (ICF), indicating agreement to comply with the requirements and restrictions in the ICF and protocol.
- Male or female, aged 18 years or older.
- Diagnosed with non-small cell lung cancer (NSCLC) with clinical staging IB, II, or IIIA.
- Receiving treatment at Hospital de Base.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment, with no decline from two weeks prior to the baseline period or the day of the first dose.
- Tumor sample meets the following requirements:
- Negative for EGFR gene expression.
- Negative for ALK and ROS1 protein expression.
- PD-L1 protein expression documented and assessable.
- Tumor is considered resectable upon initial assessment by three thoracic oncology surgeons (IR, CM, and HN) following a multidisciplinary review.
- Adequate organ and bone marrow function as defined below:
- Hemoglobin: ≥ 9.0 g/dL*
- Absolute neutrophil count: ≥ 1.5 × 10^9 /L*
- Platelet count: ≥ 100 × 10^9 /L*
- *Note: Granulocyte colony-stimulating factor (G-CSF), platelet transfusions, and blood transfusions are not permitted to meet these values.
- Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation.
- ALT and AST: ≤ 2.5 × ULN.
- Creatinine clearance: ≥ 50 mL/min (calculated using the Cockcroft and Gault formula).
- Life expectancy greater than six months prior to randomization.
Exclusion Criteria:
- Refusal to sign the Informed Consent Form (ICF).
- NSCLC clinical stages IA, IIIB N3, IIIC, IVA, and IVB.
- Tumors with T4 invasion of the aorta, esophagus, and/or heart; or presence of bulky N2 disease.
- Tumor deemed unresectable.
- Prior systemic anticancer therapy for NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational drugs.
- History of another primary malignancy, with exceptions for:
- Malignancies treated with curative intent and no active disease for ≥ 2 years before the first dose of investigational product (IP) and with a low risk of recurrence.
- Adequately treated non-melanoma skin cancer or lentigo maligna with no evidence of disease.
- Adequately treated carcinoma in situ with no evidence of disease.
- Incomplete basic medical information in the electronic medical record.
- Positive for EGFR gene expression.
- Positive for ALK protein expression.
- No available data on PD-L1 protein expression.
- Positive for ROS1 protein expression.
- Pregnant or breastfeeding at the time of enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Low-dose nivolumab combined with platinum-based doublet chemotherapy
|
Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major Pathologic Response
Time Frame: 2-3 months
|
MPR is defined as the proportion of participants who have achieved major pathologic response (on routine hematoxylin and eosin staining, tumors with no more than 10% viable tumor cells) in all participants who have completed the neoadjuvant therapy before surgery.
|
2-3 months
|
|
Pathologic Complete Response
Time Frame: 2-3 months
|
Pathological complete response (pCR) is defined as having no residual cancer at the primary site or in regional lymph nodes on pathologic review of the surgical specimen.
|
2-3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: Up to 3 months after the end of treatment
|
TRAE is defined and classified according to NCI-CTCAE v5.0 in all participants.
|
Up to 3 months after the end of treatment
|
|
Event-Free-Survival
Time Frame: Up to 60 months
|
Event-free survival (EFS) is defined as the length of time (months) from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause.
Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death.
|
Up to 60 months
|
|
R0 resection
Time Frame: Up to 3 months
|
R0 resection rate is defined as the proportion of participants who have achieved R0 resection (complete resection with no residual tumor cell in the resection margin) in all participants.
|
Up to 3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of conversion from minimally invasive surgery to open surgery
Time Frame: 2-3 months
|
The frequency at which a minimally invasive procedure needs to be converted to an open surgical approach mid-operation
|
2-3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: JOAO A SOLER, MD, Fundação Faculdade Regional de Medicina de São José do Rio Preto
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Nivolumab
Other Study ID Numbers
Other Study ID Numbers
- LungCancerLowDose
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.